Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Morrow

Showing results (291-300 of 942) with videos related to

Pageof 95
Sort By:
Critical Care Medicine|May 15, 2023
Advances in the Management of Cardiogenic ShockJacob C Jentzer, Janine Pöss, Hannah Schaubroeck, et al.
Genetics|March 29, 2011
Nitrogen metabolite repression of metabolism and virulence in the human fungal pathogen Cryptococcus neoformansI Russel Lee, Eve W L Chow, Carl A Morrow, et al.
The American Journal of Cardiology|September 18, 2004
Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS)David A Morrow, Marc S Sabatine, Elliott M Antman, et al.
Journal of Neurology|September 25, 2012
Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II studySarah A Morrow, Audrey Smerbeck, Kara Patrick, et al.
European Heart Journal|January 28, 2005
Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudyKausik K Ray, David A Morrow, C Michael Gibson, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 6, 2009
Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22Kausik K Ray, Christopher P Cannon, Richard Cairns, et al.
Diabetes, Obesity & Metabolism|May 13, 2016
Glucodynamics of long-acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trialL A Morrow, M Hompesch, S J Jacober, et al.
Molecular Cancer Research : MCR|June 26, 2014
The lipid kinase PI4KIIIβ is highly expressed in breast tumors and activates Akt in cooperation with Rab11aAnne A Morrow, Mohsen Amir Alipour, Dave Bridges, et al.
Journal of the American Heart Association|June 26, 2014
ECG morphological variability in beat space for risk stratification after acute coronary syndromeYun Liu, Zeeshan Syed, Benjamin M Scirica, et al.
Diabetes, Obesity & Metabolism|July 11, 2012
Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitusL A Morrow, M Leonsson-Zachrisson, H Ericsson, et al.
Pageof 95

Showing results (291-300 of 942) with videos related to

Sort By:
Pageof 95
Critical Care Medicine|May 15, 2023
Advances in the Management of Cardiogenic ShockJacob C Jentzer, Janine Pöss, Hannah Schaubroeck, et al.
Genetics|March 29, 2011
Nitrogen metabolite repression of metabolism and virulence in the human fungal pathogen Cryptococcus neoformansI Russel Lee, Eve W L Chow, Carl A Morrow, et al.
The American Journal of Cardiology|September 18, 2004
Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS)David A Morrow, Marc S Sabatine, Elliott M Antman, et al.
Journal of Neurology|September 25, 2012
Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II studySarah A Morrow, Audrey Smerbeck, Kara Patrick, et al.
European Heart Journal|January 28, 2005
Predictors of the rise in vWF after ST elevation myocardial infarction: implications for treatment strategies and clinical outcome: An ENTIRE-TIMI 23 substudyKausik K Ray, David A Morrow, C Michael Gibson, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 6, 2009
Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22Kausik K Ray, Christopher P Cannon, Richard Cairns, et al.
Diabetes, Obesity & Metabolism|May 13, 2016
Glucodynamics of long-acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trialL A Morrow, M Hompesch, S J Jacober, et al.
Molecular Cancer Research : MCR|June 26, 2014
The lipid kinase PI4KIIIβ is highly expressed in breast tumors and activates Akt in cooperation with Rab11aAnne A Morrow, Mohsen Amir Alipour, Dave Bridges, et al.
Journal of the American Heart Association|June 26, 2014
ECG morphological variability in beat space for risk stratification after acute coronary syndromeYun Liu, Zeeshan Syed, Benjamin M Scirica, et al.
Diabetes, Obesity & Metabolism|July 11, 2012
Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitusL A Morrow, M Leonsson-Zachrisson, H Ericsson, et al.
Pageof 95